Skip to content

Clinical efficacy observation of Zhenzhilun (sodium hyaluronate eye drops) combined with hot compress [FS-01] for xerophthalmia

Clinical efficacy observation of Zhenzhilun (sodium hyaluronate eye drops) combined with hot compress [FS-01] for xerophthalmia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076569
Enrollment
Unknown
Registered
2023-10-12
Start date
2023-04-19
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Xerophthalmia

Interventions

Observation group:Cherishun (sodium hyaluronate eye drops) Usage and dosage: Normal use is three times a day, one drop a time, if necessary can also increase the frequency of use.

Sponsors

The Third Medical Center of the Chinese People's Liberation Army General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Age =14 years old, gender is not limited; (2) Clinically diagnosed as dry eye; (3) No drugs affecting ocular surface function were used locally or throughout the body within 2 weeks; (4) Voluntarily participate in this clinical trial, give informed consent and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with eye trauma; (2) Patients with systemic immune diseases and signs of eye infection; (3) Have a history of allergy to test drug ingredients; (4) Have participated in other clinical trials within the last 3 months; (5)The investigator considered it inappropriate to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
Chinese dry eye questionnaire scale;Visual fatigue test and evaluation Scale;;

Secondary

MeasureTime frame
Tear secretion experiment;Corneal fluorescein staining score;Check tear film rupture time;

Countries

China

Contacts

Public ContactZhou Xibin

The Third Medical Center of the Chinese People's Liberation Army General Hospital

zengdujuan@guomingbosi.com+86 180 1003 9985

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026